Five Prime Therapeutics Newswire
Comprehensive Real-Time News Feed for Five Prime Therapeutics.
Results 1 - 20 of 33 in Five Prime Therapeutics
-
Roche Holding Ltd. (ADR) (RHHBY), Bristol Myers Squibb Co. (BMY):...
Biotech investors rejoice. The ASCO abstracts are here. The annual meeting of the American Society of Clinical Oncology starts on May 31, but the organization releases most of the 4,700 abstracts -- available here -- tonight. Comment?
-
Avastin linked to flesh-eating disease, prompting new label warnings
Priscilla Howard, from left, Crystal Hanna, and Nancy Haunty, all breast cancer patients, listen to testimony during a Food and Drug Administration hearing in Silver Spring, Maryland, U.S., on Tuesday, June 28, 2011. Comment?
-
Trulan Resources Inc. & Roche Holding AG Trend Analysis Report:
Trulan Resources Inc. is trading in the range of $0.2 and $0.3 in its current trading session. Comment?
-
Trulan Resources Inc. & Roche Holding AG Trend Analysis Report: (OTC...
Trulan Resources Inc. is trading in the range of $0.2 and $0.3 in its current trading session. Comment?
-
Europe midday: Portugal may receive loan extension
Acting as a backdrop, all eyes are on today's Eurogroup meeting, with the latest reports indicating that Portugal may be set to receive a large extension on its loans, of up to 7% by some accounts. Comment?
-
Severe US flu season helped Roche's Q1 sales
Strong sales of new cancer drugs and a severe U.S. flu season helped lift Swiss drug maker Roche Holding AG's revenue by 6 percent in the first quarter. Comment?
-
Five Prime, UCB team up on search for drugs
Five Prime Therapeutics Inc. and Belgian drug developer UCB S.A. will work together to discover biologic targets and drugs to treat fibrosis-related inflammatory diseases and central nervous system disorders. Comment?
-
Five Prime, UCB team up on search for drugs
Five Prime Therapeutics Inc. and Belgian drug developer UCB S.A. will work together to discover biologic targets and drugs to treat fibrosis-related inflammatory diseases and central nervous system disorders. Comment?
-
Eli Lilly and Company Sues Genentech Seeking to Invalidate Cabilly Patents
Eli Lilly & Co. sued Roche Holding AG 's Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases and order that its Erbitux drug doesn't infringe the patent. Comment?
-
Humer to step down as chairman of Roche
Swiss drugmaker Roche Holding AG says its chairman, Franz Humer, will step down next year after 13 years. Comment?
-
Eli Lilly sues Genentech seeking to invalidate Cabilly patents
w/Photo
Eli Lilly & Co. sued Roche Holding AGs Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases and order that its Erbitux drug doesn’t infringe the patent. Comment?
-
Lilly sues Genentech to invalidate Erbitux-related patents
Eli Lilly and Co. has sued Roche Holding AG's Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases, and also order that Lilly's Erbitux drug doesn't infringe the patent. Comment?
-
Roche boosts forecast for 2013 on promise of expected breast cancer drug
Roche Holding forecast that sales and profit will rise this year, helped by new products such as a breast-cancer drug that's slated for approval in February. Comment?
-
Roche posts modest profit gain for 2012
Swiss drug maker Roche Holding posted a 2.4% increase in its full year profits as demand grew for its cancer medicines and diagnostic tests used by clinical laboratories. Comment?
-
Roche Names John Reed Head Of Pharma Research, Development
Roche Holding AG Tuesday said John C. Reed, has been appointed Head of Roche Pharma Research and Early Development and member of the enlarged Corporate Executive Committee. Comment?
-
UPDATE 1-Drugmakers report U.S. shortages of flu vaccine, Tamiflu
This year's early and potentially severe flu season has created shortages of the children's formulation of the leading treatment and most forms of the top-selling flu vaccine in the United States, according to their manufacturers. Comment?
-
Regeneron Declines as Eylea Revenue Disappoints Investors
Regeneron Pharmaceuticals Inc., the drugmaker today celebrating the 25th anniversary of its incorporation, fell the most in five weeks after reporting sales for its eye drug Eylea that disappointed investors. Comment?
-
Regeneron Falls Most in 7 Months as Eylea Disappoints Investors
Regeneron Pharmaceuticals Inc., the drugmaker today celebrating the 25th anniversary of its incorporation, fell the most in seven months after reporting sales for its eye drug Eylea that disappointed investors. Comment?
-
Illumina buys Redwood City maker of Down syndrome test
Illumina, the leading manufacturer of DNA sequencing machines, said Monday that it would buy the privately held Verinata Health for at least $350 million in cash to expand its push into the diagnostics business. Comment?
-
Illumina buys Redwood City maker of Down syndrome test
Illumina, the leading manufacturer of DNA sequencing machines, said Monday that it would buy the privately held Verinata Health for at least $350 million in cash to expand its push into the diagnostics business. Comment?
Most Popular
- 1 dead after crash on LaSalle St. in Cape Girardeau - 47 comments
- Philippine President Apologizes for Taiwanese Fisherman Death - 86 comments
- Scientists agree on climate change. So why doesn't everyone else? - 37 comments
- Outgoing IRS chief deflects Republican attempts to link scandal to White House - 41 comments
- Heydar Aliyev preferred Armenian cognac - 76 comments
- Turkey and the Dream of Ottoman Revival - 30 comments
- Meat-slicing facility laying off 100 workers - 24 comments
- Woman, 37, 'stabbed boyfriend after he farted in her face during argument' - 27 comments
- George Will: IRS scandal carries echoes of Watergate - 51 comments
- Russia rejects creation of no-fly zone over Syria - 52 comments
Copyright ©2013 Topix LLC
